Urticaria medications: modern treatment regimens, antihistamines and biological therapy

Urticaria is not a single disease with a single, universal treatment, but a group of conditions in which itchy wheals, angioedema, or both appear rapidly on the skin. International guidelines define urticaria as a mast cell-mediated disorder, so the primary goal of treatment is to suppress the release of inflammatory mediators, reduce itching, eliminate wheals, and prevent recurrences. [1]

Medications are selected based on the type of urticaria: acute urticaria lasts less than 6 weeks, chronic urticaria lasts 6 weeks or longer, and induced urticaria appears after a specific stimulus—cold, pressure, heat, physical activity, vibration, water, or sunlight. This distinction is important because, with acute urticaria, a short course of symptomatic therapy is often sufficient, while chronic urticaria requires a stepwise plan with regular assessment of disease control. [2]

The main group of drugs for most forms of urticaria are modern second-generation antihistamines, which act on histamine H1 receptors. They reduce itching and wheals, are usually less drowsy than older antihistamines, and are therefore considered first-line therapy for acute, chronic spontaneous, and chronic induced urticaria. [3]

If the standard dose of a modern antihistamine is ineffective for chronic urticaria, international recommendations allow for a dose increase of up to four times the recommended dose, but no higher. This does not mean the patient should increase the dosage independently: any dose increase should be discussed with a physician, taking into account age, pregnancy, liver and kidney disease, drowsiness, driving, and drug interactions. [4]

If urticaria is accompanied by shortness of breath, wheezing, swelling of the tongue or throat, weakness, fainting, a drop in blood pressure, or repeated vomiting after a potential allergen, it's no longer simply a question of "which pill to take." This could be anaphylaxis, in which the first drug of choice is adrenaline, with antihistamines playing only a supporting role. [5]

Clinical situation	What is usually used	What is important to remember
Acute urticaria without dangerous symptoms	A modern 2nd generation antihistamine	Treatment is usually short-term, but an assessment of the cause is necessary.
Chronic spontaneous urticaria	Regular antihistamine, then dose increase, then targeted therapy	Treatment is selected in stages, based on symptom control.
Inducible urticaria	Avoidance of stimulus plus antihistamine	The provoking factor cannot always be completely excluded
Urticaria with signs of anaphylaxis	Adrenaline and emergency aid	Anti-itch tablets are not a substitute for emergency treatment.
Persistent chronic urticaria	Omalizumab, dupilumab, remibrutinib, or cyclosporine as indicated	Availability and indications vary by country and clinical situation.

Second-generation antihistamines: the basis of treatment

Modern second-generation antihistamines are considered the mainstay of treatment for urticaria because they block the action of histamine on H1 receptors in the skin. This group includes cetirizine, levocetirizine, loratadine, desloratadine, fexofenadine, bilastine, rupatadine, and some other drugs, the availability of which varies by country. [6]

Their advantage over older first-generation medications lies not only in their ease of administration but also in their improved safety profile. Older medications, such as diphenhydramine, chloropyramine, clemastine, and hydroxyzine, are more likely to cause drowsiness, impaired attention, dry mouth, urinary retention, and risk of falls in the elderly, so current guidelines do not consider them the best option for the routine management of chronic urticaria. [7]

For chronic urticaria, antihistamines are usually more effective when taken regularly, rather than just "when an outbreak occurs." Regular use helps maintain histamine receptor blockade, reduces the severity of itching, and decreases the unpredictability of flare-ups, especially in chronic induced urticaria, where the trigger cannot always be avoided. [8]

For acute urticaria, a doctor may prescribe an antihistamine for several days or until symptoms resolve, and for chronic urticaria, for weeks or months, with periodic evaluation of the effect. If the medication is well tolerated but insufficiently effective, it is common to first increase the dose of the same modern antihistamine, rather than haphazardly mixing several different medications. [9]

The choice of a specific antihistamine depends on the patient's age, risk of drowsiness, pregnancy, breastfeeding, liver and kidney disease, occupation, concomitant medications, and personal response. Even drugs within the same class can be tolerated differently: one person responds better to fexofenadine, another to cetirizine or bilastine, so switching medications is sometimes justified if the standard option fails to provide control. [10]

International nonproprietary name	Peculiarities	Practical place in therapy
Cetirizine	Effective, but may cause drowsiness in some people	A common starting option
Levocetirizine	The active isomer of cetirizine	Suitable for insufficient response or intolerance to other agents
Loratadine	Usually low sedation	Suitable for daytime use in many patients
Desloratadine	Active metabolite of loratadine	Used for acute and chronic urticaria
Fexofenadine	Minimal penetration into the central nervous system	Often chosen when necessary to maintain concentration
Bilastine	A modern low-sedative drug	May be useful for chronic conditions
Rupatadine	Additionally affects platelet activating factor	May be considered for chronic urticaria

What to do if the usual dose doesn't help

In chronic urticaria, failure to respond to a standard dose of antihistamine does not mean the diagnosis is incorrect or that treatment is futile. Guidelines recommend a stepwise approach: first use a modern second-generation antihistamine at the usual dose, then increase the dose to four times the usual dose if control is insufficient, and if symptoms persist, move on to targeted therapy. [11]

A dose increase of up to four times the recommended dose is more often used for chronic urticaria than for any occasional rash. Patients should be advised that such an increase may be considered off-label in many countries, although it is supported by international guidelines and has long been used in clinical practice. [12]

Doses higher than 4 times the recommended dose are not recommended because they have not been adequately tested and are not part of a modern safety algorithm. If a 4-fold dose fails to provide control, it is best not to continue increasing the antihistamine load indefinitely, but to move on to the next step of therapy—usually omalizumab or another targeted agent as indicated. [13]

Systemic glucocorticosteroids, such as prednisolone or methylprednisolone, should not be used as a chronic treatment for chronic urticaria. International updates emphasize that long-term use of systemic steroids should be avoided, and short rescue courses should only be considered for severe exacerbations when the benefits outweigh the risks. [14]

The use of histamine H2 receptor blockers or leukotriene receptor antagonists varies across countries, but they are not central to current international regimens. They may be found in individual local protocols, but for severe chronic spontaneous urticaria, the key next-line options remain omalizumab, dupilumab, remibrutinib, or cyclosporine, depending on indication and availability. [15]

Treatment step	What do they usually do?	When they move on
Step 1	A modern 2nd generation antihistamine in a standard dose	If itching, blisters, or angioedema persists
Step 2	Increase the dose to 4 times under the supervision of a physician	If there is no control despite a sufficient period of treatment
Step 3	Omalizumab or another approved targeted drug	If high doses of antihistamines don't help
Step 4	Cyclosporine in selected patients	If the disease is severe and other options are ineffective or unavailable
Rescue measure	Short course of systemic steroid	Only in severe exacerbations, not as a permanent regimen

Omalizumab: The leading biologic agent for chronic spontaneous urticaria

Omalizumab is a monoclonal antibody against immunoglobulin E used to treat chronic spontaneous urticaria in patients whose symptoms persist despite treatment with antihistamines. The official information for the drug states that it is indicated for adults and adolescents aged 12 years and older with chronic spontaneous urticaria if symptoms persist despite treatment with H1-receptor-active antihistamines. [16]

In the United States, omalizumab is administered subcutaneously for chronic spontaneous urticaria at 150 mg or 300 mg every 4 weeks, with the dosage for this indication independent of immunoglobulin E levels and body weight. A number of European regimens more commonly recommend 300 mg every 4 weeks as the standard option for patients with an insufficient response to antihistamines. [17]

Omalizumab is not intended for the treatment of acute anaphylaxis, is not a "rescue shot," and does not replace epinephrine in the event of a serious allergic reaction. Furthermore, omalizumab carries a warning about the risk of anaphylaxis after administration, so initiation of therapy and subsequent monitoring should comply with local safety regulations. [18]

The effect of omalizumab is assessed not on a day-to-day basis, but rather by the dynamics of itching, wheals, angioedema, sleep quality, and the need for additional medications. If the drug is effective, the patient typically achieves more stable disease control, but the duration of therapy and the decision to reduce or discontinue it should be discussed with the physician, as relapse is possible in some patients after discontinuation. [19]

Omalizumab's primary use is for chronic spontaneous urticaria, but its use in chronic induced urticaria may be restricted by country-specific drug registration. Data on induced forms, such as symptomatic dermographism or cold urticaria, exist, but use in such situations often requires specialized decision-making and informed patient consent. [20]

Parameter	Omalizumab
Class	Monoclonal antibody against immunoglobulin E
Main place	Chronic spontaneous urticaria with inadequate response to antihistamines
Age according to official indication in the USA	Adults and teenagers from 12 years old
Introduction	Subcutaneously every 4 weeks
Important limitation	Not for emergency treatment of anaphylaxis
Special risk	Severe hypersensitivity reactions, including anaphylaxis, may occur.

Dupilumab and remibrutinib: new targeted options

Dupilumab is a monoclonal antibody that blocks the interleukin-4 and interleukin-13 signaling pathways, which are involved in type 2 inflammation. In 2025, the US Food and Drug Administration approved it for adults and adolescents 12 years and older with chronic spontaneous urticaria that persists despite treatment with antihistamines, and in 2026, the indication was expanded to children 2 to 11 years old. [21]

The current full prescribing information for dupilumab is indicated for adults and children 2 years of age and older with chronic spontaneous urticaria, if symptoms persist despite treatment with H1-receptor-active antihistamines. The same prescribing information also explicitly states a limitation: dupilumab is not intended for the treatment of other forms of urticaria. [22]

Remibrutinib is an orally administered Bruton tyrosine kinase inhibitor that targets intracellular pathways that activate mast cells and basophils. In 2025, it was approved in the United States for adult patients with chronic spontaneous urticaria that persists despite treatment with antihistamines, and in 2026, it received approval from the European Commission as the first oral targeted therapy for this indication.[23]

The US label for remibrutinib lists a dose of 25 mg orally twice daily with or without food; the drug is not indicated for other forms of urticaria. The label also includes important warnings: risk of bleeding, the need for a temporary break before and after surgery, avoidance of live vaccines, and drug interactions via the cytochrome P450 3A4 system. [24]

In practice, this means that the treatment of chronic spontaneous urticaria after antihistamine failure has become more widespread than it was just a few years ago. However, the choice between omalizumab, dupilumab, remibrutinib, and cyclosporine depends on country, drug registration, age, concomitant asthma or atopic dermatitis, risk of infection, risk of bleeding, pregnancy, cost, and response to previous therapies. [25]

Preparation	Class	Who is it being considered for?	Peculiarities
Omalizumab	Anti-immunoglobulin E antibody	Chronic spontaneous urticaria after antihistamines	Subcutaneous administration, extensive experience of use
Dupilumab	Antibody to interleukin-4 alpha receptor	Chronic spontaneous urticaria with persistence of symptoms after antihistamines	May be of particular interest in type 2 inflammation and associated diseases
Remibrutinib	Bruton tyrosine kinase inhibitor	Adults with chronic spontaneous urticaria after antihistamines	Oral targeted drug, interactions and bleeding risk are important
Cyclosporine	Immunosuppressant	Severe refractory chronic urticaria	Requires monitoring of blood pressure, kidney function and drug interactions

Cyclosporine and systemic steroids: when they are needed and why they should be used with caution

Cyclosporine can be used for severe chronic spontaneous urticaria when antihistamines and biological therapy are ineffective or unavailable. It targets immune mechanisms of inflammation, but is not a simple "itch medication" because it requires strict safety monitoring. [26]

The main limitations of cyclosporine are the risk of increased blood pressure, renal impairment, drug interactions, and widespread immunosuppression. Therefore, this drug is not suitable for self-administration, should not be prescribed without evaluating contraindications, and requires laboratory monitoring, especially during long-term treatment. [27]

Systemic glucocorticosteroids can rapidly reduce severe inflammatory flare-ups, but they should not be used as a chronic treatment for chronic urticaria. Long-term steroid use is associated with an increased risk of diabetes, hypertension, osteoporosis, infections, weight gain, cataracts, and suppression of hormonal regulation. [28]

A short course of systemic steroids may be justified in severe flare-ups, severe angioedema, or excruciating itching, when rapid relief is needed. However, if urticaria returns after each steroid withdrawal, this is a sign that a new prednisolone regimen is needed, rather than a new pack of prednisolone. [29]

Hormonal ointments for common urticaria are usually ineffective because the wheal in urticaria does not appear as eczema on the skin's surface, but as rapid swelling in the dermis under the influence of mast cell mediators. Therefore, topical glucocorticosteroids may be appropriate for other dermatoses, but are not a standard treatment for chronic urticaria. [30]

Drug group	When might it be needed?	Main risks
Cyclosporine	Severe chronic urticaria after failure of previous treatments	Pressure, kidneys, infections, interactions
Systemic steroids	Short course for severe exacerbation	Metabolic complications, osteoporosis, infections with long-term use
Topical steroid ointments	Usually not the primary treatment for hives	Masking of another diagnosis, skin atrophy when used incorrectly
Long-acting injectable steroids	Usually undesirable without strict indications	Long-term systemic action and difficulty of withdrawal

Medicines for acute urticaria and urticaria with angioedema

Acute urticaria is most often associated with infections, foods, medications, insect bites, or an unknown short-term trigger. If there are no signs of anaphylaxis, the mainstay of treatment is usually a modern second-generation antihistamine, which reduces itching and wheals until the reaction subsides.[31]

If there is angioedema of the lips, eyelids, or face, the situation requires a more careful assessment, as swelling can be part of a common urticaria, but it can also be an early sign of a dangerous systemic reaction. Particularly worrisome are swelling of the tongue, uvula, or throat, hoarseness, difficulty swallowing, shortness of breath, wheezing, weakness, or fainting. [32]

For acute urticaria caused by medication, it's important not just to "remove the rash," but to record the name of the drug, the dose, the time of administration, and the time of symptom onset. This will help the doctor distinguish a true drug allergy from a coincidence, a viral rash, intolerance, or an exacerbation of chronic urticaria. [33]

If acute urticaria occurs after eating, it's not always necessary to completely eliminate all foods eaten that day. It's better to record the ingredients of the dish, sauces, additives, alcohol, physical activity, painkiller use, and the frequency of the reaction, and then, if necessary, undergo an allergy evaluation. [34]

If the wheals resolve but then return almost daily and last longer than 6 weeks, the tactic changes: this is already chronic urticaria, where searching for “one allergen” is often less useful than assessing the activity of the disease and proper step therapy. [35]

Situation	Possible tactics	When to see a doctor urgently
Acute urticaria without systemic symptoms	A modern antihistamine	If the rash gets worse quickly or swelling occurs
Hives after medication	Stop the suspected drug only after risk assessment and consult a doctor	If there is shortness of breath, weakness, swelling of the tongue or throat
Hives after eating	Write down the products and circumstances	If there is vomiting, shortness of breath, fainting or a drop in blood pressure
Hives with swelling of the lips or eyelids	Medical assessment, antihistamine as prescribed	If the swelling extends to the tongue or throat
Symptoms lasting longer than 6 weeks	Evaluation of chronic urticaria	If the quality of life is sharply reduced or there is angioedema

Special patient groups

For children, medications for urticaria are selected based on age, body weight, dosage form, and national instructions. Modern reviews and guidelines mention bilastine, cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, and rupatadine among antihistamines with pediatric data, but the specific choice should be made by a physician based on the child's age. [36]

Pregnant and breastfeeding women should not automatically tolerate adult treatment regimens for chronic urticaria without assessing the benefits and risks. The physician considers the severity of symptoms, the gestational age, the safety history of the specific antihistamine, the need to avoid sedatives, and the risk of worsening the condition if treatment is discontinued completely. [37]

Older sedating antihistamines are particularly undesirable in older adults because they can increase drowsiness, confusion, dry mucous membranes, urinary retention, and the risk of falls. For this group, modern low-sedation medications are more often chosen, and renal and hepatic function and interactions with existing medications are carefully assessed. [38]

In patients with bronchial asthma, cardiovascular disease, chronic kidney disease, liver disease, or autoimmune diseases, drug selection requires greater caution. For example, cyclosporine may be problematic in patients with hypertension and renal impairment, and remibrutinib requires consideration of the risk of bleeding and drug interactions. [39]

In patients with chronic urticaria and a significant decrease in quality of life, it is important to evaluate not only the skin but also sleep, performance, anxiety, frequency of exacerbations, angioedema, and the need for rescue medications. International guidelines emphasize that chronic urticaria can significantly disrupt education, work, and daily life, so the goal of treatment is not "tolerable itching," but maximum disease control. [40]

Patient group	What to consider when choosing a drug
Children	Age, body weight, release form, drug registration
Pregnant women	Balance of benefits and risks, minimally adequate therapy
Breastfeeding women	The drug enters breast milk and drowsiness in the child
Elderly	Risk of falls, cognitive impairment, and drug interactions
Patients with kidney disease	Possible dose adjustments for individual drugs
Patients with severe chronic urticaria	Indications for targeted therapy and safety monitoring

Common mistakes in treating urticaria

The first mistake is to treat any urticaria solely with older sedative antihistamines. They can indeed reduce itching, but they more often cause drowsiness and cognitive impairment, so current recommendations favor second-generation medications. [41]

The second mistake is taking an antihistamine only occasionally for chronic urticaria, even though symptoms occur almost daily. In chronic cases, regular use often provides better control than constant "catch-up" treatment for an already developed flare-up. [42]

The third mistake is using systemic steroids for months because they quickly relieve symptoms. This approach can create steroid dependence and serious complications, whereas the modern strategy for chronic urticaria should be steroid-sparing. [43]

The fourth mistake is endlessly searching for food allergies in chronic spontaneous urticaria without a clear connection to the foods involved. In chronic spontaneous urticaria, the cause is often not determined by a single allergen, so extreme dieting can worsen nutrition and quality of life without improving disease control. [44]

The fifth mistake is confusing hives with anaphylaxis and hoping that an anti-itch pill will resolve the dangerous reaction. If wheals are accompanied by shortness of breath, swelling of the tongue or throat, weakness, fainting, or a drop in blood pressure, an emergency approach is required, not the usual hives treatment regimen. [45]

Error	Why is this bad?	What is more correct?
Constantly use old sedatives	Drowsiness, risk of mistakes and falls	Start with 2nd generation drugs
Increase the dose on your own	Risk of side effects and incorrect dosage	Increase the dose only with the advice of a doctor.
Taking steroids for a long time	High risk of systemic complications	Use only briefly for severe exacerbations.
Eliminate dozens of products without evidence	Risk of deficiencies and anxiety	Look for connections through diary and examination
Ignore signs of anaphylaxis	Risk of life-threatening deterioration	Call emergency help

FAQ

What medications for urticaria are considered first-line treatment? In most cases, these are modern second-generation antihistamines that act on histamine H1 receptors: cetirizine, levocetirizine, loratadine, desloratadine, fexofenadine, bilastine, rupatadine, and other drugs available in a particular country. [46]

Can antihistamines be taken every day? For chronic urticaria, daily regular use is often the correct regimen because it helps maintain symptom control and reduce the frequency of flare-ups. [47]

Is it possible to increase the antihistamine dose? For chronic urticaria, international recommendations allow for increasing the dose of modern second-generation antihistamines up to four times the normal dose, but this decision should be made by a physician, and doses higher than four times the normal dose are not recommended. [48]

Which is better: cetirizine, loratadine, or fexofenadine? There is no universal "best" drug: all are modern antihistamines, but they differ individually in their effectiveness, sedation, drug interactions, and ease of administration. [49]

Is prednisolone necessary for urticaria? Prednisolone and other systemic steroids can be used only for short periods during severe flare-ups, but should not be used as a permanent treatment for chronic urticaria. [50]

When is omalizumab prescribed? Omalizumab is considered for chronic spontaneous urticaria in adults and adolescents 12 years of age and older if symptoms persist despite treatment with antihistamines. [51]

How does dupilumab differ from omalizumab? Omalizumab targets immunoglobulin E, while dupilumab blocks the interleukin-4 and interleukin-13 signaling pathways; both drugs can be used for chronic spontaneous urticaria according to their indications, but the choice depends on age, availability, comorbidities, and previous treatments. [52]

What is remibrutinib? Remibrutinib is an oral Bruton tyrosine kinase inhibitor approved for adults with chronic spontaneous urticaria that persists despite antihistamine therapy; it is not indicated for other forms of urticaria.[53]

Do ointments help with hives? For common hives, ointments, including hormonal ones, are usually not the primary treatment because the problem is related to the rapid release of mast cell mediators in the skin, rather than superficial inflammation like eczema. [54]

When does hives require urgent care? Urgent care is needed if hives are accompanied by shortness of breath, wheezing, swelling of the tongue or throat, weakness, fainting, a drop in blood pressure, or repeated vomiting after exposure to a possible allergen, as this may indicate anaphylaxis. [55]

Key points from experts

Professor Torsten Zuberbier, a dermatologist and allergist and one of the leading authors of international guidelines on urticaria, attributes the modern approach to a precise classification of the disease and stepwise treatment. The practical implication of these guidelines is simple: first, understand the type of urticaria, then achieve complete symptom control, rather than simply temporarily reducing itching. [56]

Professor Marcus Maurer, a specialist at the Charité Institute of Allergy and one of the most renowned researchers of chronic urticaria, emphasized the role of mast cells, itching, and inflammation in the mechanisms of the disease. This leads to an important clinical principle: in severe chronic urticaria, treatment should target not only histamine but also deeper immune mechanisms if antihistamines are ineffective. [57]

Allen P. Kaplan, MD, clinical professor of medicine at the Medical University of South Carolina and a recognized expert on urticaria and angioedema, has described chronic spontaneous urticaria in detail as a condition characterized by intense itching, wheals, angioedema, and decreased quality of life. His work helps explain why chronic urticaria cannot be considered a "simple allergic rash." [58]

Ana M. Giménez-Arnau, a dermatologist, professor at Pompeu Fabra University, and specialist in cutaneous allergy and photobiology, has been actively involved in studies of chronic spontaneous urticaria and omalizumab. Her expertise is important for practice: in chronic urticaria, it is important to evaluate not only the resolution of wheals but also itching, sleep, quality of life, angioedema, and the persistence of control. [59]

The current expert consensus can be formulated as follows: medications for urticaria should be selected stepwise, starting with safe second-generation antihistamines, systemic steroids should not be overused, targeted therapy should be switched to in a timely manner in severe chronic cases, and normal urticaria should always be distinguished from anaphylaxis. [60]